FY2026 Earnings Forecast for NVO Issued By Erste Group Bank

Novo Nordisk A/S (NYSE:NVO) – Investment analysts at Erste Group Bank upped their FY2026 earnings per share (EPS) estimates for Novo Nordisk A/S in a research note issued to investors on Thursday, August 27th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $3.46 for the year, up from their prior estimate of $3.27. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.45 per share. Erste Group Bank also issued estimates for Novo Nordisk A/S’s FY2027 earnings at $3.34 EPS.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The company had revenue of $11.98 billion for the quarter.

Other equities analysts have also issued reports about the stock. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Finally, Berenberg Bank set a $47.00 price target on Novo Nordisk A/S in a report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S Trading Down 0.5%

Shares of Novo Nordisk A/S stock opened at $45.11 on Monday. The stock has a market capitalization of $201.42 billion, a P/E ratio of 11.03, a price-to-earnings-growth ratio of 4.05 and a beta of 0.75. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company has a 50-day simple moving average of $47.98 and a 200 day simple moving average of $43.80. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of large investors have recently modified their holdings of NVO. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $287,660,000. Boston Partners bought a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $310,199,000. Price T Rowe Associates Inc. MD lifted its holdings in Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after buying an additional 4,836,285 shares in the last quarter. Voloridge Investment Management LLC lifted its holdings in Novo Nordisk A/S by 851.6% during the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after buying an additional 4,302,126 shares in the last quarter. Finally, Maverick Capital Ltd. bought a new position in Novo Nordisk A/S in the 1st quarter valued at $76,444,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a $0.5786 dividend. This represents a yield of 258.0%. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 20.05%.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill launches in Germany: Germany is the first European Union market to receive Novo Nordisk’s oral Wegovy, giving the company an opportunity to expand treatment access and test demand for a more convenient weight-loss option. Novo Nordisk launches Wegovy weight-loss pill in Germany
• Positive Sentiment: CagriSema provides a potential pipeline catalyst: Novo’s combination obesity drug remains under U.S. regulatory review, offering a possible way to narrow the competitive gap with Eli Lilly if approved and successfully commercialized. Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
• Positive Sentiment: Share repurchases offer support: Novo Nordisk is continuing a buyback program of up to DKK 15 billion over 12 months, which could provide technical support and signal management’s view that the shares are undervalued. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Early Wegovy-pill rollout is being closely watched: Investors are assessing whether the German launch can translate into meaningful sales growth while Eli Lilly expands its competing oral and injectable GLP-1 offerings. Novo Nordisk, What Is Behind The Fresh Attention?
• Neutral Sentiment: A study found that patients remaining on low starter doses of GLP-1 drugs may lose some weight with less nausea, but also potentially receive less weight-loss benefit than patients reaching recommended doses. GLP-1 weight loss drugs effective even at low starter doses
• Negative Sentiment: Competitive and execution concerns persist: Coverage highlights a more crowded GLP-1 market, Novo’s recent underperformance, and skepticism about whether its pipeline can close the gap with Eli Lilly. A rating downgrade also reinforces the cautious investor view. Novo Nordisk: Why The Price Remains Stubbornly Low

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.